# OnCo record nct05128487 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05128487/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05128487", "NCT05128487" ;
  schema:name "A Study of NDI 1150-101 in Patients With Solid Tumors"@en ;
  schema:description "A phase 1/2 trial of Pembrolizumab in renal cell carcinoma and non-small-cell lung cancer, run by Nimbus Saturn, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05128487/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05128487> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2021-11-05" ;
  onco:cancers <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/sclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/nimbus-therapeutics/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct05128487-cell-rep-med-2026/> .